Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
16 nov. 2020 08h00 HE
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...
Retrophin Reports Third Quarter 2020 Financial Results
05 nov. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
09 oct. 2020 16h01 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
21 sept. 2020 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
Retrophin Reports First Quarter 2020 Financial Results
11 mai 2020 16h01 HE
|
Retrophin, Inc.
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
09 mars 2020 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
24 févr. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Retrophin to Present at Upcoming Investor Conferences
19 févr. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March:...
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the...
Retrophin Reports Third Quarter 2019 Financial Results
30 oct. 2019 16h01 HE
|
Retrophin, Inc.
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...